[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dyspnoea\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dyspnoea":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100627216","sports-shoes-and-the-six-minute-walk-test-in-copd-100627216",false,"NCT07445750","Sports Shoes and the Six-Minute Walk Test in COPD","Impact of High Biomechanical Efficiency Footwear on Six-Minute Walk Test Performance in Chronic Obstructive Pulmonary Disease (COPD): A Randomised Cross-Over Controlled Trial","ChaussePnee","Inclusion Criteria:\n\n* Age 18 or older\n* Diagnosed with COPD according to standard criteria\n* Severe to very severe airflow obstruction (FEV₁ \\\u003C 50% predicted, within 12 months)\n* Dyspnoea grade 3 or 4 on the mMRC scale\n* Currently hospitalised in the respiratory rehabilitation unit\n* Clinical indication for six-minute walk test\n* Provided written informed consent\n\nNon inlcusion Criteria:\n\n* Any respiratory condition other than COPD\n* Neurological, neuromuscular, orthopaedic or rheumatological conditions affecting gait or balance\n* Uncorrected visual or hearing impairment\n* Cognitive or psychiatric disorders interfering with instructions\n* Contraindications to exercise testing (e.g. unstable angina, recent myocardial infarction, severe uncontrolled hypertension, resting HR \\>120 bpm)\n* Pregnancy or breastfeeding\n* Inability to understand French\n* No health insurance coverage\n* Under legal protection (e.g. guardianship)\n* Participation in another interventional or randomised clinical trial\n* Habitual use of active sports shoes","ALL","18 Years",{"count":20,"type":21},75,"ESTIMATED","INTERVENTIONAL",[24],"NA","COPD: A Leading Cause of Respiratory Disability COPD, primarily linked to smoking, affects 3.5 million people in France and causes 15,000 deaths each year. It is a major source of disability, particularly due to dyspnoea, which affects one in three patients. Around 400,000 patients are registered under long-term conditions (ALD), and 200,000 receive home-based respiratory support. The most severe cases fall under the category of chronic respiratory failure-a term also applicable to other respiratory or neuromuscular diseases.\n\nWalking Exposes Physical Limitations In patients with respiratory failure, walking rapidly induces disabling dyspnoea, as it may represent their maximal effort. This severely limits autonomy and quality of life. To improve exercise tolerance, clinicians rely on pulmonary rehabilitation (exercise reconditioning, bronchodilators, oxygen therapy). When these measures are insufficient, mobility aids such as scooters or electric scooters may help, although they have limitations (cost, bulkiness, muscular deconditioning).\n\nThe Six-Minute Walk Test (6MWT): A Key Tool The 6MWT is a standardised test that assesses walking distance, dyspnoea, heart rate, and oxygenation. It is used to evaluate the severity and prognosis of respiratory failure and to measure response to treatment. It is integrated into prognostic indices and criteria for assessing the effectiveness of rehabilitation. The only non-standardised parameter remains the type of footwear worn.\n\nResearch Hypothesis Some so-called \"active\" sports shoes enhance walking by design-through cushioning, rocker soles, and rigid inserts-which store and return impact energy to assist propulsion. We hypothesise that wearing such shoes could improve walking performance in COPD patients, as reflected by a greater distance on the 6MWT. If confirmed, this simple and low-cost solution could meaningfully improve the daily lives of many patients.",[27,28,29],"Chronic Obstructive Pulmonary Disease (COPD)","Dyspnoea","Exercise Intolerance",[31,32,28,33,34,35,36,37,38,39,40],"COPD","Six-Minute Walk Test","Active Footwear","Gait","Biomechanics","Pulmonary Rehabilitation","Stair Climbing","Oxygen Saturation","Exercise Capacity","Respiratory Disability","NOT_YET_RECRUITING","2026-02-25",{"date":44,"type":45},"2026-03-03","ACTUAL",{"date":47,"type":21},"2026-04-01",{"date":49,"type":21},"2027-04-01",{"name":51,"class":52},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100569299","acute-heart-failure-in-elderly-patients-admitted-to-the-emergency-department-with-acute-dyspnea-a-multimarker-approach-prognostic-study-100569299","NCT06692439","Acute Heart Failure in Elderly Patients Admitted to the Emergency Department with Acute Dyspnea: a Multimarker Approach Prognostic Study","READ-MA-PRONO","Inclusion Criteria: Patients aged ≥75 years from the READ cohort (NCT04240067) who:\n\n1. Present to the ED with acute dyspnea meeting at least two criteria:\n\n   * Respiratory rate ≥25\u002Fmin\n   * PaO2 ≤70 mmHg\n   * SpO2 ≤92% on room air\n   * PaCO2 ≥45 mmHg and pH ≤7.35\n   * Oxygen requirement\n2. Have confirmed AHF diagnosis by two expert reviewers based on clinical data, laboratory results (excluding NT-proBNP), ECG, imaging, and specialized cardiac echo\n3. Provided written consent for data use in the READ-MA-PRONO study\n\nExclusion Criteria:\n\n* No written consent for data use in the READ-MA-PRONO study","75 Years",{"count":63,"type":21},185,"OBSERVATIONAL","Background and Rationale:\n\nAcute dyspnea is a frequent presenting symptom in emergency departments (ED), with acute heart failure (AHF) being the most common cause leading to hospitalization in elderly patients. AHF in this population presents unique challenges in diagnosis, management, and risk stratification. Current tools for severity assessment and risk stratification (NT-proBNP and echocardiography) have shown limited evolution over the past 20 years and remain insufficient, particularly for elderly patients who predominantly present with heart failure with preserved ejection fraction (HFpEF). Recent European Society of Cardiology (ESC) and American Heart Association (AHA) guidelines specifically call for research on biomarkers within a multi-marker strategy for AHF risk stratification.\n\nResearch Hypothesis:\n\nThe study hypothesizes that a combination of biomarkers (NT-proBNP, High-sensitivity Troponin I, ST2, Galectin-3, CD146 and suPAR) will provide prognostic value and effectively stratify risk for early outcomes (90-day mortality and hospital readmission) in patients aged ≥75 years presenting to the ED with acute dyspnea and diagnosed with AHF.\n\nPrimary Objective:\n\nTo evaluate the prognostic value of six biomarkers, both individually and in combination, for predicting 90-day all-cause mortality or ED readmission in elderly patients (≥75 years) presenting with acute dyspnea and diagnosed with AHF.\n\nStudy Design:\n\nThis is a prospective prognostic study including patients from 7 emergency departments from university and non-university hospitals in France.\n\nStudy Population:\n\n(I) Patients aged ≥75 years presenting to the ED with acute dyspnea meeting at least two criteria:\n\n* Respiratory rate ≥25\u002Fmin\n* PaO2 ≤70 mmHg\n* SpO2 ≤92% on room air\n* PaCO2 ≥45 mmHg and pH ≤7.35\n* Oxygen requirement\n\n(ii) Have confirmed AHF diagnosis by two expert reviewers based on clinical data, laboratory results (excluding NT-proBNP), ECG, imaging, and specialized cardiac echo\n\nPrimary Endpoint:\n\nComposite endpoint of 90-day all-cause mortality or ED readmission, as recommended by the ESC for evaluating early outcomes in AHF patients.\n\nAnalysis plan includes:\n\n* ROC curves for optimal biomarker thresholds\n* Kaplan-Meier survival analysis with log-rank tests\n* Univariate and multivariate Cox regression analyses\n* Bootstrap methods for confidence intervals",[67,28],"Acute Heart Failure (AHF)",[69,70,71,72],"acute heart failure","dyspnea","prognosis","biomarkers","2024-11-14",{"date":75,"type":45},"2024-11-18",{"date":77,"type":21},"2024-11",{"date":79,"type":21},"2025-09",{"name":81,"class":52},"Centre Hospitalier Universitaire de Besancon"]